Havemeyer Place LP Makes New $1.17 Million Investment in Medpace Holdings, Inc. $MEDP

Havemeyer Place LP purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,086 shares of the company’s stock, valued at approximately $1,172,000.

Several other institutional investors have also recently made changes to their positions in MEDP. Cibc World Market Inc. bought a new stake in shares of Medpace in the 3rd quarter valued at approximately $5,033,000. Capital Fund Management S.A. lifted its stake in shares of Medpace by 129.5% in the 3rd quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock valued at $16,665,000 after purchasing an additional 18,287 shares during the last quarter. Dorsey Wright & Associates bought a new stake in shares of Medpace in the 3rd quarter valued at approximately $5,082,000. Victory Capital Management Inc. lifted its stake in shares of Medpace by 32.9% in the 3rd quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock valued at $15,702,000 after purchasing an additional 7,565 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its stake in shares of Medpace by 9.9% in the 3rd quarter. Fisher Asset Management LLC now owns 137,746 shares of the company’s stock valued at $70,824,000 after purchasing an additional 12,399 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Analysts Set New Price Targets

A number of brokerages recently issued reports on MEDP. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Robert W. Baird decreased their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Barclays decreased their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Truist Financial decreased their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. Finally, Leerink Partners decreased their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $467.08.

Insider Buying and Selling at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.50% of the company’s stock.

Medpace Stock Performance

Shares of MEDP stock opened at $454.25 on Monday. The stock has a 50 day moving average price of $456.73 and a 200 day moving average price of $508.39. The firm has a market capitalization of $12.97 billion, a P/E ratio of 28.55, a P/E/G ratio of 2.30 and a beta of 1.18. Medpace Holdings, Inc. has a 52-week low of $294.07 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.